Isopropylphenidate (iPPH; IPPH) is a synthetic stimulant of the substituted phenidate chemical class — a structural analog of methylphenidate (Ritalin) in which the methyl ester is replaced by an isopropyl ester. This modification produces several clinically relevant differences from methylphenidate: notably, isopropylphenidate is not efficiently metabolized by carboxylesterase-1 to a ritalinic acid analog in the presence of ethanol, reducing the ethanol transesterification risk that is a specific concern for methylphenidate and ethylphenidate.
Isopropylphenidate acts as a dopamine and norepinephrine reuptake inhibitor through binding to DAT and NET — the core phenidate-class mechanism — without the releasing agent activity of amphetamines. This produces a characteristically smoother, less "sharp" stimulation than amphetamines, valued by users seeking functional cognitive enhancement without the intensity or cardiovascular activation of releasing agents. Community reports describe it as producing clean focus, moderate motivation enhancement, and mild mood elevation broadly comparable to methylphenidate but with a somewhat longer duration.
The compound gained particular attention in the harm reduction community as the UK Psychoactive Substances Act (2016) scheduled most phenidate RCs, and iPPH was developed partly as a structural modification that might provide a legal path. It subsequently became one of the more widely discussed phenidate alternatives in European harm reduction communities. In vivo rat studies confirm stimulatory effects; in vitro transporter binding characterization has been conducted, giving iPPH slightly more pharmacological documentation than some research chemicals. Nevertheless, formal human pharmacological and long-term safety data remain absent.
Safety at a Glance
High Risk- Alcohol Interaction Is Still Cautioned
- Based on methylphenidate dose ratios and limited community reports:
- Toxicity: Acute Toxicity Profile No formal human toxicity data exist for isopropylphenidate. Based on the phenidate class mecha...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from Isopropylphenidate is a medical emergency primarily involving cardiovascu...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 2.5 hrs – 4 hrsoral
Total: 3.5 hrs – 6 hrsHow It Feels
Isopropylphenidate settles into the mind like a well-organized desk. Within thirty to sixty minutes of oral ingestion, the clutter of unfocused thoughts begins to clear, and what remains is a calm, structured attentiveness. There is no rush, no surge of energy, no perceptible shift in mood. Instead, there is simply a quiet improvement in the ability to direct and sustain attention. Tasks that had been avoided suddenly seem approachable. The distance between intention and action shortens measurably. It is as though someone has gently increased the resolution of executive function while leaving everything else untouched.
At its functional peak, reached around one to two hours in, isopropylphenidate produces what might be described as the distilled essence of a study drug. Concentration is markedly enhanced and can be maintained for extended periods. Distractibility decreases. Working memory improves. The experience is almost entirely cognitive, with little to no recreational value: there is no euphoria, no increased sociability, no enhanced sensory perception. The world does not become more interesting. It simply becomes more workable. This austerity is the compound's defining feature, making it perhaps the most purely functional stimulant in its class.
The physical effects are minimal and largely peripheral. Heart rate may increase slightly, appetite diminishes, and there is a mild dryness of the mouth. The hands remain steady, the body comfortable, and the overall physical load is lighter than methylphenidate or ethylphenidate. Nasal administration is possible but less common, and the compound's relatively gentle physical profile makes it one of the better-tolerated members of the phenidate family.
The duration is moderate, with the primary effects lasting three to five hours. The offset is gradual and benign, a slow return to baseline attentiveness without the irritability, headache, or rebound fog that can accompany the comedown from more potent stimulants. Sleep is achievable within a few hours of the effects wearing off. The aftereffects are negligible. The overall experience leaves a peculiarly hollow impression, not because it was unpleasant but because there is so little to say about it beyond its utility. It works. It does what it is supposed to do. It does nothing more. For a study aid, this is perhaps the highest possible praise.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(11)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(15)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
Isopropylphenidate acts primarily as a dopamine reuptake inhibitor at DAT, with secondary norepinephrine reuptake inhibition at NET. Unlike amphetamines, it does not reverse transporter direction and does not produce large-scale active neurotransmitter release. The reuptake inhibition mechanism produces a smoother dopamine elevation curve compared to releasing agents, contributing to the lower intensity but generally cleaner subjective profile.
In vitro studies have characterized isopropylphenidate's binding affinities at monoamine transporters, confirming preferential DAT affinity over NET, with minimal SERT activity — consistent with a non-entactogenic, purely cognitive stimulant profile.
Receptor Profile
- DAT — Primary target; dopamine reuptake inhibition drives focus and mild euphoria
- NET — Secondary; norepinephrine reuptake inhibition produces wakefulness, appetite suppression
- SERT — Minimal activity; no entactogenic or serotonergic effects
Esterase Resistance
Unlike methylphenidate and ethylphenidate, the isopropyl ester of iPPH is substantially more resistant to carboxylesterase-1 hydrolysis. This means:
- It is not efficiently converted to ethylphenidate in the presence of ethanol (reducing the key transesterification risk)
- It has slower hydrolysis overall, potentially contributing to extended duration
- Metabolic profiles may differ substantially from methylphenidate
Pharmacokinetics
Based on rat studies and community reports:
- Onset: 30–60 minutes oral
- Duration: 4–6 hours (somewhat longer than methylphenidate's 3–4 hour duration)
- Bioavailability: Expected similar to methylphenidate via oral route
Detection Methods
Standard Drug Panel Inclusion
Isopropylphenidate is a phenidate-class stimulant that is not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. Phenidates are structurally distinct from amphetamines and do not cross-react with amphetamine or methamphetamine antibodies used in commercial immunoassays. There is no dedicated phenidate channel on any standard workplace or clinical drug panel.
Urine Detection
Isopropylphenidate and its primary metabolite ritalinic acid (or the corresponding deesterified acid analogue) can be detected in urine for approximately 1 to 3 days after a single oral dose. The ester bond in phenidate compounds is rapidly hydrolyzed by plasma and hepatic esterases, producing the corresponding acid metabolite which is the dominant species found in urine. Higher doses or repeated administration may extend the detection window modestly.
Blood and Saliva Detection
Blood concentrations of Isopropylphenidate decline rapidly due to ester hydrolysis, with a detection window of approximately 6 to 24 hours for the parent compound. The acid metabolite persists longer in plasma, detectable for up to 48 hours. Oral fluid testing can detect the parent compound for approximately 12 to 36 hours, though this route of detection is rarely employed for phenidates in practice.
Hair Follicle Detection
Hair follicle analysis may detect Isopropylphenidate or its metabolites for up to 90 days. However, incorporation of phenidate-class compounds into hair has not been extensively studied, and commercial laboratories do not routinely test for these substances. Specialized forensic laboratories with LC-MS/MS capability and appropriate reference standards would be required.
Confirmatory Testing
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for confirming the presence of Isopropylphenidate and its metabolites. The ester bond in phenidates makes them somewhat labile under GC-MS conditions, so LC-MS/MS is preferred. Both parent compound and the deesterified acid metabolite should be targeted for comprehensive analysis.
Reagent Testing
Marquis reagent typically shows no reaction or a very faint color change with Isopropylphenidate, which helps distinguish it from amphetamines (orange-brown) and MDMA (purple-black). Mecke reagent generally shows no reaction. Mandelin reagent may produce a faint yellow or no change. The absence of strong reagent reactions is characteristic of the phenidate class and is itself a useful piece of information when combined with other reagent results.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Development Context
Isopropylphenidate was developed as a structural modification of methylphenidate — specifically, replacement of the methyl ester with an isopropyl ester. This modification was recognized as providing pharmacological differences (esterase resistance) alongside the legal advantage of being a different chemical entity.
UK Regulatory Context
iPPH emerged partly in response to UK and European scheduling of more common phenidate RCs including ethylphenidate. The Psychoactive Substances Act 2016 in the UK created demand for alternatives that might remain accessible; iPPH received attention in this context, though the PSA effectively covered all psychoactives rather than specific chemicals, limiting its legal loophole value in the UK.
Community Reception
In harm reduction communities, iPPH has been received relatively positively as a phenidate-class stimulant with better-understood risks than some alternatives, a reasonable duration, and the specific advantage of reduced ethanol transesterification risk. It remains one of the more commonly discussed phenidate alternatives in European and North American nootropic/RC communities.
Harm Reduction
Oral Route Only
Insufflation of phenidate esters causes local vasoconstriction and mucosal irritation. The ester groups are hydrolyze on mucous membranes, potentially producing local irritation from free acid formation. Oral or sublingual administration is preferred.
Alcohol Interaction Is Still Cautioned
While iPPH's reduced esterase susceptibility lowers the transesterification risk compared to ethylphenidate, the general cardiovascular and pharmacodynamic risks of combining any CNS stimulant with alcohol remain. Avoiding alcohol during use is still recommended.
Dose Reference
Based on methylphenidate dose ratios and limited community reports:
- Threshold: 5 mg oral
- Common: 10–20 mg oral
- Strong: 20–30 mg oral
Start low given the limited human data.
Avoid Daily Use
Tolerance develops with regular phenidate use. Daily use leads to diminishing returns and increasing side effect burden. Intermittent use with drug holidays is recommended.
Drug Interactions
Toxicity & Safety
Acute Toxicity Profile
No formal human toxicity data exist for isopropylphenidate. Based on the phenidate class mechanism, acute risks are primarily cardiovascular — tachycardia, hypertension, arrhythmia at high doses — consistent with sympathomimetic dopaminergic/noradrenergic stimulation.
Reduced Ethanol Transesterification Risk
Compared to methylphenidate and ethylphenidate, the isopropyl ester is substantially more resistant to carboxylesterase-1 conversion in the presence of ethanol. This reduces — though may not eliminate — the specific transesterification-mediated pharmacokinetic risk that makes phenidate-alcohol combinations particularly hazardous. This is a genuine safety advantage of iPPH over other phenidates.
Cardiovascular Risk
Standard stimulant cardiovascular risks apply. The reuptake inhibitor mechanism generally produces lower peak dopamine concentrations than releasing agents, potentially providing some protective margin.
Dependence
Physical and psychological dependence potential comparable to methylphenidate class. Compulsive use of phenidate RCs is documented in community harm reduction literature.
Unknown Long-Term Risks
The esterase-resistant metabolic pathway means the metabolites of iPPH may differ substantially from those of methylphenidate. Without metabolite identification studies, long-term metabolic risks cannot be fully characterized.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from Isopropylphenidate is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Germany: Isopropylphenidate is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: Isoprpoylphenidate is a controlled substance specifically named under Verzeichnis E.
Turkey: Isopropylphenidate is illegal in Turkey as of February 2016.
United Kingdom: Isopropylphenidate is a class B drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply.
Canada: Isopropylphenidate is a Schedule III drug in Canada.
Responsible use
Designer drug
Stimulant
Isopropylphenidate (Wikipedia)
Isopropylphenidate (Isomer Design)
Markowitz, J. S., Zhu, H., & Patrick, K. S. (2013). Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. Journal of Child and Adolescent Psychopharmacology, 23(10), 648-654. https://doi.org/10.1089/cap.2013.0074
John S. Markowitz; Kennerly S. Patrick; Haojie Zhu (Sep 27, 2012). "Patent US20120245201 - Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions". Retrieved 15 August 2014.
Experience Reports (1)
Tips (7)
Do not combine Isopropylphenidate with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
Start low with Isopropylphenidate and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Eat a substantial meal before taking Isopropylphenidate. Stimulants suppress appetite heavily, and going many hours without food leads to worse crashes, irritability, and cognitive impairment. Set phone reminders to eat and drink.
Isopropylphenidate (IPPH) is considered one of the milder phenidate stimulants, with less pronounced euphoria and cardiovascular effects than ethylphenidate or methylphenidate. It is often described as a functional stimulant suitable for productivity rather than recreation. This relatively mild profile also means less compulsive redosing urge.
Typical oral doses range from 15-30mg. Onset is within 30-60 minutes with effects lasting 3-5 hours. As with all phenidate compounds, insufflation increases bioavailability and cardiovascular stress. Oral dosing is preferred from a harm reduction standpoint.
IPPH has an available patent with preclinical safety data, which is more information than exists for most research chemical stimulants. However, there are no human clinical trials. Treat it as you would any novel research chemical: start low, use infrequently, and monitor for unusual side effects.
Community Discussions (1)
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Isopropylphenidate
PubChem compound page for Isopropylphenidate (CID: 68314762)
pubchem - Isopropylphenidate - TripSit Factsheet
TripSit factsheet for Isopropylphenidate
tripsit - Isopropylphenidate - Wikipedia
Wikipedia article on Isopropylphenidate
wikipedia